Purpose: Tumor/node/metastasis staging and prognostic index (PI) are used to predict prognosis and guide treatment for anaplastic thyroid carcinoma (ATC). With the advent of treatments, such as BRAF/MEK inhibitors and immune checkpoint inhibitors, dynamic markers to assess disease status and treatment efficacy are needed. This study examined the utility of PI as a dynamic marker for ATC treatment.
Methods: This retrospective study investigated 20 patients with ATC who were treated aggressively from January 2011 to December 2022. Patients were categorized into low-, high-, low-, and high-high groups according to the PI before and after treatment. Survival was then compared between the groups.
Results: The median overall survival was not reached for the Low-Low, 363 days for the High-Low, 158.5 days for the Low-High, and 90.5 days for the High-High groups (p < 0.01). Among the 13 patients with an initially high PI, 6 patients achieved a low PI during treatment, but three showed subsequent increases. Categorizing PI further into decreased, temporarily decreased, and non-decreased groups, median overall survival was 363 days, 158.5 days, and 87 days, respectively (p < 0.01).
Conclusion: PI is a critical prognostic indicator that facilitates treatment decision-making for ATC. PI may also have potential as a dynamic marker for assessing the disease status and treatment efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-024-02991-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing.
Arch Med Res
January 2025
Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea; Center for Precision Medicine and Genomics, Wonju Severance Christian Hospital, Wonju, South Korea. Electronic address:
Background: Lymphoma is a common hematological malignancy with diverse morphological and immunophenotypic characteristics that may affect treatment and outcomes. Thus, accurate differential diagnosis is crucial, and molecular genetic testing is valuable. We aimed to investigate the genetic characteristics of Korean patients with lymphoma using a next-generation sequencing (NGS)-based targeted panel.
View Article and Find Full Text PDFBrain metastasis has emerged as a significant challenge in the comprehensive management of patients with non-small cell lung cancer (NSCLC), particularly in those harboring driver gene mutations. Traditional treatments such as radiotherapy and surgery offer limited clinical benefits and are often accompanied by cognitive dysfunction and a decline in quality of life. In recent years, novel small molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other pathways have been developed, effectively penetrating the blood-brain barrier while enhancing intracranial drug concentrations and improving patient outcomes.
View Article and Find Full Text PDFDynamics of the prognostic index during the course of treatment for anaplastic thyroid carcinoma.
Surg Today
January 2025
Department of Endocrine Surgery, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Purpose: Tumor/node/metastasis staging and prognostic index (PI) are used to predict prognosis and guide treatment for anaplastic thyroid carcinoma (ATC). With the advent of treatments, such as BRAF/MEK inhibitors and immune checkpoint inhibitors, dynamic markers to assess disease status and treatment efficacy are needed. This study examined the utility of PI as a dynamic marker for ATC treatment.
View Article and Find Full Text PDFHigh-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma: Correlating Extent of Invasion and Mutation Profile with Oncologic Outcome.
Thyroid
January 2025
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
The 2022 World Health Organization classification introduced the term high-grade follicular cell-derived nonanaplastic thyroid carcinoma (HGFCTC) to define invasive/infiltrative nonanaplastic thyroid carcinoma with high-grade features, including poorly differentiated thyroid carcinoma and high-grade differentiated thyroid carcinoma. Our objectives were to compare clinicopathological characteristics, oncologic outcomes, and mutation profiles among HGFCTC subgroups to better inform prognostication and treatment. In this single-center, retrospective cohort study of 252 patients who had surgery for HGFCTC from 1986 to 2020, we categorized HGFCTC and its related entity, "encapsulated noninvasive neoplasms of follicular cells with high-grade features," into five subgroups: (A) encapsulated noninvasive, (B) encapsulated with capsular invasion only (minimally invasive), (C) encapsulated angioinvasive with focal vascular invasion (VI), (D) encapsulated angioinvasive with extensive VI, and (E) infiltrative tumors.
View Article and Find Full Text PDFIntroduction: Anal Lymphoma (AL) is a rare presentation of extranodal lymphomas, characterized by occurrence in the anal area and largely understudied due to its infrequency. This study aims to address gaps in knowledge about AL's demographic and clinical profiles, treatments, and survival outcomes, leveraging data from the SEER program.
Methods: We conducted a retrospective analysis of 79 AL cases identified in the SEER database from 2000 to 2022; 36 stage I AL were identified and defined as localized primary anal lymphoma (L-PAL).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!